Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer.

Abstract

Twenty-five women with advanced breast cancer were treated in a phase II trial of iproplatin 275 mg/m2 administered intravenously every 4 weeks. All patients had measurable or evaluable indicator lesions, and had undergone treatment with no more than one previous chemotherapy regimen, including adjuvant chemotherapy. Two of the twenty-four evaluable patients (8%) experienced major therapeutic responses. One patient had a complete regression of pulmonary nodules lasting 18+ months; another had a partial regression of metastatic disease in the liver (4 months). The inevaluable patient was ineligible for the study because of previous radiation to the indicator lesions on her chest wall; nonetheless, she experienced a 10 month partial regression of those nodules. Myelosuppression was generally dose limiting; thrombocytopenia was more profound, but leukopenia was more prolonged. Nausea, vomiting, diarrhea, and general malaise were prominent toxicities, and led to discontinuation of therapy in 4 patients. Iproplatin has limited activity in previously treated women with advanced breast cancer.

• Authors: E S Casper, T C Smart, T B Hakes, M Ochoa Jr, R J Kaufman
• Journal: Investigational new drugs (Invest New Drugs) Vol. 6 Issue 2 Pg. 87-91 (Jun 1988) ISSN: 0167-6997 [Print] United States
• PMID: 3049433 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• iproplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Bone Marrow (drug effects)
• Breast Neoplasms (drug therapy)
• Clinical Trials as Topic
• Female
• Humans
• Middle Aged
• Organoplatinum Compounds (adverse effects, therapeutic use)